<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629871</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL18_0061</org_study_id>
    <nct_id>NCT05629871</nct_id>
  </id_info>
  <brief_title>Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?</brief_title>
  <acronym>ALZ-OREX</acronym>
  <official_title>Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive&#xD;
      function. In the early stages of AD, there is a progressive accumulation of molecules:&#xD;
      β-amyloid peptides (Aβ) in the brain. There is a link between the accumulation of Aβ peptides&#xD;
      and the deterioration of sleep, but current knowledge does not confirmed this link. The&#xD;
      objective of this study is to define whether there is a link between cognitive decline and&#xD;
      sleep disorders. If a correlation is found, this could allow earlier treatment of sleep&#xD;
      disorders in the longer term in order to slow the development of AD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2023</start_date>
  <completion_date type="Anticipated">June 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Free and Cued Selective Reminding Test (FCSRT) scale score</measure>
    <time_frame>From inclusion to 24 months</time_frame>
    <description>The FCSRT test evaluates memory, the score obtained is between 0 and 48, higher score mean a better outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Free and Cued Selective Reminding Test (FCSRT) scale score</measure>
    <time_frame>From inclusion to 12 months</time_frame>
    <description>The FCSRT test evaluates memory, the score obtained is between 0 and 48, higher score mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive decline in ADCS-PACC composite score</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>The ADCS-PACC composite score is used to assess cognitive decline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive decline in the Alzheimer's Disease Cooperative Study- Preclinical Alzheimer Cognitive Composite (ADCS-PACC) composite score</measure>
    <time_frame>At inclusion and at 12 months</time_frame>
    <description>The ADCS-PACC composite score is used to assess cognitive decline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of proteins involved in Alzheimer disease</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>Determination of Aβ42, Aβ40, Tau and P-Tau proteins in serum and cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of orexinA/hypocretin</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>Determination in serum and cerebrospinal fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sleep duration</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>Average sleep duration (in hours and minutes) over a 14-day period from inclusion to M24 measured by actimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep time at stage 1-2 during polysomnography</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>Time spent in stage 1-2 sleep measured in hours and minutes during polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep time at stage 3 during polysomnography</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>Time spent in stage 3 sleep measured in hours and minutes during polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in Rapid eye movement (REM) sleep during polysomnography</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>Time spent in stage 3 sleep measured in hours and minutes during polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea Hypopnea Index</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>The Apnea-Hypopnea Index is calculated from the number of apneas and hypopneas per hour of sleep (AHI = number of apneas + number of hypopneas / number of hours of sleep) during polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal oxygen saturation (SaO2)</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>The nocturnal SaO2 is an average of SaO2 values taken during the night. The value is expressed as a percentage and is measured during polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary melatonin concentration</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>Fractional diuresis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Internal temperature</measure>
    <time_frame>At inclusion and at 24 months</time_frame>
    <description>The internal temperature will be measured with an e-Celsius capsule during polysomnography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Neuropathology</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alzheimer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Polysomnography</intervention_name>
    <description>Polysomnography will be performed for 24 hours at inclusion and 24 months</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Neuropsychological assessment</intervention_name>
    <description>A full neuropsychological assessment will be performed at inclusion, 12 and 24 months</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires on sleep and behavioural problems</intervention_name>
    <description>Questionnaires on sleep and behavioural problems</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Actimetry</intervention_name>
    <description>Measurement of actimetrics for 14 days at inclusion and at 24 months</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fractional diuresis</intervention_name>
    <description>Split diuresis from 7pm-7am, 7am-12am and 12pm-19pm during polysomnography at inclusion inclusion and 24 months to measure melatonin concentration</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Internal temperature measurement</intervention_name>
    <description>eCelsius capsule to measure internal temperature at inclusion and 24 months</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker assay</intervention_name>
    <description>Determination of the biomarkers Aβ42, Aβ40, Tau and P-Tau in blood and in the cerebrospinal fluid</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of mild Alzheimer's disease with a Mini Mental State (MMS) between 21-30&#xD;
&#xD;
          -  The presence of a family carer to complete neuropsychological scales, questionnaires&#xD;
             and sleep diaries&#xD;
&#xD;
          -  Having a neurological assessment and/or follow-up requiring blood and cerebrospinal&#xD;
             fluid (CSF) sampling with biomarkers for diagnostic purposes&#xD;
&#xD;
          -  Patient who had a lumbar puncture less than one year ago or patient with a scheduled&#xD;
             lumbar puncture as part of care&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Able to carry out all visits and follow study procedures&#xD;
&#xD;
          -  Affiliation to the French social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Genetic form of alzheimer's disease&#xD;
&#xD;
          -  Insufficient clinical and paraclinical information for the diagnosis of AD&#xD;
&#xD;
          -  Anticholinesterase and/or memantine treatment or on stable doses for at least 3 months&#xD;
&#xD;
          -  Use of antidepressants, anxiolytics, hypnotics, neuroleptics, 15 days before inclusion&#xD;
&#xD;
          -  Patient living in a nursing home&#xD;
&#xD;
          -  Illiteracy or inability to perform psycho-behavioural tests&#xD;
&#xD;
          -  Major physical or neurosensory problems that may interfere with the tests&#xD;
&#xD;
          -  Initial contraindication to diagnostic lumbar puncture (LP) (spinal surgery, skin&#xD;
             infection, haemostasis abnormality, intracranial hypertension, severe coagulation&#xD;
             disorders, curative anticoagulant therapy, severe liver failure)&#xD;
&#xD;
          -  Refusal to perform a diagnostic lumbar puncture&#xD;
&#xD;
          -  Contraindication to the use of E-Celsius: people weighing less than 40 kg, with&#xD;
             intestinal disorders, with known swallowing disorders&#xD;
&#xD;
          -  Patient deprived of liberty, by judicial or administrative decision;&#xD;
&#xD;
          -  Major protected by law;&#xD;
&#xD;
          -  Patient in a period of relative exclusion from another protocol or for whom the&#xD;
             maximum annual compensation of €4500 has been reached;&#xD;
&#xD;
          -  Refusal to participate in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim BENNYS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yves Dauvilliers, MD</last_name>
    <phone>+33467335219</phone>
    <email>y-dauvilliers@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital, Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Karim BENNYS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Karim BENNYS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc PACCALIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marc PACCALIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Rachel DEBS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rachel DEBS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>October 28, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>January 12, 2023</last_update_submitted>
  <last_update_submitted_qc>January 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognitive composite score</keyword>
  <keyword>sleep</keyword>
  <keyword>biomarkers</keyword>
  <keyword>cognitive decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

